Wearable Devices in Clinical Trials: Hype and Hypothesis

A foundational framework for validating wearable devices and digital biomarkers in biopharmaceutical research.

What the Research Covers

Drawing on experience across therapeutic areas, the review examines the scientific, regulatory, legal, and operational hurdles that stand between a wearable sensor and a defensible clinical trial outcome measure. It centers on a framework that has since become the industry standard for evaluating digital measures:

• Context of use (COU): Why a wearable-derived measure must be evaluated against the specific disease, population, and clinical question it’s meant to address, not treated as a generic sensor output.
• Analytical validation: Establishing that a device accurately and reliably measures the physiological signal it claims to capture (e.g., heart rate, gait, sleep, skin temperature).
• Clinical validation: Confirming that the validated signal actually corresponds to a meaningful clinical concept, function, symptom burden, or disease progression, for the population under study.
• Technology landscape: A survey of actigraphy, ambulatory ECG and blood pressure monitoring, EEG, galvanic skin response, oximetry, skin temperature sensing, mobile applications, and medication adherence tools, with real-world examples of successful implementation.

Why It Matters for Clinical Trial Sponsors

For teams building decentralized and hybrid clinical trials, this review remains a practical starting point for answering the question regulators and IRBs will ask first: how do you know this device measurement is fit for purpose? Rather than treating wearable data collection as a plug-and-play add-on, the authors argue for a structured validation pathway, one that connects raw sensor output to a clinically meaningful, regulatory-defensible endpoint before it ever appears in a statistical analysis plan.

The result is a roadmap that has shaped how sponsors, CROs, and digital health innovators approach:

• Remote patient monitoring and continuous data collection
• Digital biomarker and digital endpoint development
• Wearable sensor selection and validation strategy
• Regulatory readiness for FDA and EMA submissions involving novel technologies